Authorized purpose: Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population
Clinical role
Second-reader CADe detection and localization, operating as an adjunct to physician review rather than standalone clinical decision-making
Images and patients
X-ray/Radiography · Chest/lung, focused on suspected pulmonary nodules
Key limitation
Keep in mind: Incidental adult population and frontal AP/PA digital chest radiographs only; target range 6-30 mm; adjunctive second-reader information, not standalone clinical decision-making and not a substitute for the original radiograph
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/lung, focused on suspected pulmonary nodules Input: DICOM frontal AP or PA digital chest radiographs of adults; effective target nodule size 6-30 mm
Who uses it?Intended users: Radiologists, emergency-room physicians, or pulmonologists who regularly review chest X-rays
What does the software produce?Output: DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition
What is its most important limitation?Key limitation: Incidental adult population and frontal AP/PA digital chest radiographs only; target range 6-30 mm; adjunctive second-reader information, not standalone clinical decision-making and not a substitute for the original radiograph
Clinical takeaway. Clinical role: Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population
Evidence takeaway. Evidence from the reviewed source record: Standalone study covered 8 states and 40 US sites, with ground truth from five ABR-certified readers using chest radiographs plus CT and reports. qXR-LN nodule-level sensitivity was 84.1% (reported CI 77.97%-97.24%) and FPPI 0.18 (0.14-0.22). Scan-level AUC was 94.51 (92.64-96.66), sensitivity 93.83 (88.94-97.00), and specificity 81.09 (76.30-85.00). In the MRMC second-read study, AFROC was 0.8095 aided versus 0.7333 unaided, delta 0.07621, p<1e-5; nodule-level sensitivity improvement was 11.96 percentage points
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Second-reader CADe to identify and mark suspected pulmonary nodules 6-30 mm in the incidental adult population
DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition
Incidental adult population and frontal AP/PA digital chest radiographs only; target range 6-30 mm; adjunctive second-reader information, not standalone clinical decision-making and not a substitute for the original radiograph
Standalone study covered 8 states and 40 US sites, with ground truth from five ABR-certified readers using chest radiographs plus CT and reports. qXR-LN nodule-level sensitivity was 84.1% (reported CI 77.97%-97.24%) and FPPI 0.18 (0.14-0.22). Scan-level AUC was 94.51 (92.64-96.66), sensitivity 93.83 (88.94-97.00), and specificity 81.09 (76.30-85.00). In the MRMC second-read study, AFROC was 0.8095 aided versus 0.7333 unaided, delta 0.07621, p<1e-5; nodule-level sensitivity improvement was 11.96 percentage points
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Standalone study covered 8 states and 40 US sites, with ground truth from five ABR-certified readers using chest radiographs plus CT and reports. qXR-LN nodule-level sensitivity was 84.1% (reported CI 77.97%-97.24%) and FPPI 0.18 (0.14-0.22). Scan-level AUC was 94.51 (92.64-96.66), sensitivity 93.83 (88.94-97.00), and specificity 81.09 (76.30-85.00). In the MRMC second-read study, AFROC was 0.8095 aided versus 0.7333 unaided, delta 0.07621, p<1e-5; nodule-level sensitivity improvement was 11.96 percentage points
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
qXR-LN regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231805
Sites40
IndependenceIndependence not established
K231805
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231805. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM frontal AP or PA digital chest radiographs of adults; effective target nodule size 6-30 mm
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Images are sent through a PACS or other radiological image-storage system, and the device is intended for use with any DICOM viewer or PACS; exact local interface/version compatibility is not established
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM output with ROI markings on a duplicated input image showing the presence and location of suspected pulmonary nodules; output is for adjunctive review and does not rule out the target condition
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Images are sent through a PACS or other radiological image-storage system, and the device is intended for use with any DICOM viewer or PACS; exact local interface/version compatibility is not established
Qure.ai's documentation FAQ says data is sent over HTTPS (TLS 1.2 or higher), stored encrypted at rest with AES-256-GCM, backed up with restore tests twice a year, and that Qure maintains an ISO 27001 certification with periodic surveillance audits. It also says hospitals anonymize PHI before sending data. The certificate itself was not read and no date or scope is given.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Qure.ai's vulnerability disclosure programme states that it covers all Qure.ai commercial products, including cloud-hosted products and Qure.ai-operated infrastructure, and commits to handling every report promptly and transparently with an acknowledgement and tracking reference within 2 business days.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Qure.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established. The programme is an intake and response-handling commitment; it makes no uptime, drift or continuous-monitoring claims.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
2Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K231805 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: VisiRad XR is a computer-aided detection device that identifies and marks regions of interest suspicious for lung nodules and masses measuring 6-60 mm on chest radiographs in patients older than 21 years in outpatient or emergency-department settings.
Modality
X-ray/Radiography
Anatomy
Adult chest and pulmonary nodules or masses 6-60 mm
Authorized purpose: RAPIDSCREEN RS-2000 is a PMA-authorized computer-aided detection device that identifies and marks regions of interest on digitized frontal chest radiographs associated with solitary pulmonary nodules 9-30 mm, as an aid after the physician's initial interpretation.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Authorized purpose: Analyze frontal chest and abdominal X-ray images to detect and localize a nasally or orally inserted enteric tube, its tip and side port if present, and the diaphragm and airways for radiologist review.
Modality
X-ray/Radiography
Anatomy
Chest/lung and abdomen/stomach; enteric tube, tube tip and side port, diaphragm, and airways including carina and left/right bronchi
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.